[Oxiracetam treatment of exogenous post-concussion syndrome. Statistical evaluation of results].
The aim of the study was to evaluate the clinical use of a GABOB by-product in the treatment of exogenous post-concussion syndrome. Thirty-six patients affected by this syndrome were included in the study and divided into two groups. Patients in the first group were treated with the drug, while patients in the second group were not treated. Variations in the average time taken for symptoms to disappear in both groups showed a statistically significant difference in favour of the drug-treated group of patients. Following an analysis of the results it was possible to affirm that the drug had a statistically significant effect in patients affected by medium-severe symptomatology.
Russello
D
D
Cattedra Patologia Speciale Chirurgica CO, Università degli Studi di Catania.
Randazzo
G
G
Favetta
A
A
Cristaldi
C
C
Petino
A G
AG
Carnazzo
S A
SA
Latteri
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001924:Brain Concussion / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011759:Pyrrolidines / Q000627:therapeutic use*; D013577:Syndrome
D011759:Pyrrolidines; C040619:oxiracetam
Trattamento con oxiracetam della sindrome post-commotiva esogena. Valutazione statistica dei risultati.